Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Novus Therapeutics
TKAI

Buy Novus Therapeutics (TKAI) Stock

TKAI
See TKAI stock price and Buy/Sell Novus Therapeutics with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
TKAI

Novus Therapeutics (TKAI)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Novus Therapeutics (TKAI)

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD4...Read more
Market Cap
$44.03M
1 Year High
$9.90
Volume
22.56k
1 Year Low
$2.27
Price to Earnings Ratio
Open
$3.25
Dividend Rate
High
$3.25
Dividend Yield
Low
$3.08

Community

People who own or watch TKAI stock

Novus Therapeutics stock rating

What analysts recommend for TKAI stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
1

Novus Therapeutics price target

What analysts think TKAI will be worth
Low $2.27
High $28.80
Current $3.19
Target $28.80

Novus Therapeutics earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.23
-0.47
-0.7
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022

Expected EPS
Q2 2022
-$0.70
Actual EPS
Q2 2022

Buy Novus Therapeutics (TKAI) Stock

TKAI
See TKAI stock price and Buy/Sell Novus Therapeutics with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch TKAI stock
  • usmc6132 avatar
  • Jordy2892 avatar
  • brettjames1972 avatar
  • Sitvatgroup avatar
  • bernadeauj avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.